Format

Send to

Choose Destination
Bioorg Med Chem. 2013 Apr 15;21(8):2241-2249. doi: 10.1016/j.bmc.2013.02.009. Epub 2013 Feb 18.

VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid.

Author information

1
ReveraGen BioPharma, Inc., 9700 Great Seneca Hwy Rockville, MD 20910, United States. Electronic address: erica.reeves@reveragen.com.
2
ReveraGen BioPharma, Inc., 9700 Great Seneca Hwy Rockville, MD 20910, United States; Center for Genetic Medicine Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC 20010, United States; Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, United States.
3
ReveraGen BioPharma, Inc., 9700 Great Seneca Hwy Rockville, MD 20910, United States.
4
ReveraGen BioPharma, Inc., 9700 Great Seneca Hwy Rockville, MD 20910, United States; PharMac, LLC, P.O. Box 2253, Boca Grande, FL 33921 United States.

Erratum in

  • Bioorg Med Chem. 2015 Apr 1;23(7):1664.

Abstract

Δ9,11 modifications of glucocorticoids (21-aminosteroids) have been developed as drugs for protection against cell damage (lipid peroxidation; lazaroids) and inhibition of neovascularization (anecortave). Part of the rationale for developing these compounds has been the loss of glucocorticoid receptor binding due to the Δ9,11 modification, thus avoiding many immunosuppressive activities and deleterious side effect profiles associated with binding to glucocorticoid and mineralocorticoid receptors. We recently demonstrated that anecortave acetate and its 21-hydroxy analog (VBP1) do, in fact, show glucocorticoid and mineralocorticoid receptor binding activities, with potent translocation of the glucocorticoid receptor to the cell nucleus. We concluded that Δ9,11 steroids showed novel anti-inflammatory properties, retaining NF-κB inhibition, but losing deleterious glucocorticoid side effect profiles. Evidence for this was developed in pre-clinical trials of chronic muscle inflammation. Here, we describe a drug development program aimed at optimizing the Δ9,11 chemistry. Twenty Δ9,11 derivatives were tested in in vitro screens for NF-κB inhibition and GR translocation to the nucleus, and low cell toxicity. VBP15 was selected as the lead compound due to potent NF-κB inhibition and GR translocation similar to prednisone and dexamethasone, lack of transactivation properties, and good bioavailability. Phamacokinetics were similar to traditional glucocorticoid drugs with terminal half-life of 0.35 h (mice), 0.58 h (rats), 5.42 h (dogs), and bioavailability of 74.5% (mice), and 53.2% (dogs). Metabolic stability showed ≥80% remaining at 1 h of VBP6 and VBP15 in human, dog, and monkey liver microsomes. Solubility, permeability and plasma protein binding were within acceptable limits. VBP15 moderately induced CYP3A4 across the three human hepatocyte donors (24-42%), similar to other steroids. VBP15 is currently under development for treatment of Duchenne muscular dystrophy.

PMID:
23498916
PMCID:
PMC4088988
DOI:
10.1016/j.bmc.2013.02.009
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center